Results 71 to 80 of about 12,288 (265)

Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial

Emerging Microbes and Infections, 2023
Antibody persistence and safety up to 12 months of heterologous orally administered adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in individuals who were primed with two-dose inactivated SARS-CoV-2 vaccine (CoronaVac) previously, has not ...
Lairun Jin, Rong Tang, Shipo Wu, Xiling Guo, Haitao Huang, Lihua Hou, Xiaoqin Chen, Tao Zhu, Jinbo Gou, Jin Zhong, Hongxing Pan, Lunbiao Cui, Yin Chen, Xin Xia, Jialu Feng, Xue Wang, Qi Zhao, XiaoYu Xu, Zhuopei Li, Xiaoyin Zhang, Wei Chen, Jingxin Li, Fengcai Zhu   +22 more
doaj   +1 more source

The effectiveness and safety of mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines among individuals with chronic kidney diseases [PDF]

, 2022
The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed a serious threat to individuals with underlying chronic kidney disease (CKD).
Chan, EWY, Cheng, FWT, Chui, CSL, Fan, M, Lai, FTT, Li, X, Tang, SCW, Wan, EYF, Wong, CKH, Wong, ICK   +9 more
core  

Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study [PDF]

, 2023
BACKGROUND: People with substance use disorder have a high risk of SARS-CoV-2 infection and subsequent poor outcomes. Few studies have evaluated COVID-19 vaccine effectiveness among people with substance use disorder.
Castle, David J, Chan, Esther W, Chang, Wing Chung, Chui, Celine SL, Chung, Albert KK, Cowling, Benjamin J, Hayes, Joseph F, Huang, Caige, Kang, Wei, Lai, Francisco TT, Lau, Chak Sing, Li, Xue, Shami, Jessica JP, Tse, Man Li, Wan, Eric YF, Wei, Yue, Wong, Carlos KH, Wong, Ian CK, Yan, Vincent KC, Ye, Xuxiao, Yiu, Hei Hang Edmund   +20 more
core  

Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case–control study [PDF]

, 2022
Data regarding protection against mortality and severe complications after Omicron BA.2 infection with CoronaVac and BNT162b2 vaccines remains limited. We conducted a case–control study to evaluate the risk of severe complications and mortality following
Chan, Esther Wai Yin, Chui, Celine Sze Ling, Chui, William Chun Ming, Cowling, Benjamin John, Lai, Francisco Tsz Tsun, Lau, Chak Sing, Leung, Gabriel Matthew, Li, Philip Hei, Li, Xue, Ma, Tiantian, Mok, Anna Hoi Ying, Qin, Simon, Tsang, Tat Chi, Tsui, Sik Hon, Wan, Eric Yuk Fai, Wong, Carlos King Ho, Wong, Ian Chi Kei, Wong, Vincent Kai Chung, Yan, Vincent Ka Chun, Ye, Xuxiao   +19 more
core   +1 more source

Pityriasis rosea following CoronaVac COVID‐19 vaccination: a case report

Journal of the European Academy of Dermatology and Venereology, 2021
According to official data published by the World Health Organization, more than 100 million cases worldwide have been confirmed to be infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), causing over two million deaths. The CoronaVac vaccine, an inactivated vaccine candidate against COVID-19 containing inactivated SARS-CoV-2, is
E. Akdaş, N. İlter, B. Öğüt, Ö. Erdem   +3 more
openaire   +3 more sources

Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster

Antibodies, 2022
Introduction: We documented the total spike antibody (S-Ab), IgG S-Ab and neutralizing antibody (N-Ab) responses of BNT162b2/CoronaVac vaccinees up to 90 days post-booster dose.
Chin Shern Lau, John Thundyil, May Lin Helen Oh, Soon Kieng Phua, Ya Li Liang, Yanfeng Li, Jianxin Huo, Yuhan Huang, Biyan Zhang, Shengli Xu, Tar Choon Aw   +10 more
doaj   +1 more source

Heterologous Booster with BNT162b2 Induced High Specific Antibody Levels in CoronaVac Vaccinees

Vaccines, 2023
Immune responses after COVID-19 vaccination should be evaluated in different populations around the world. This study compared antibody responses induced by ChAdOx1 nCoV-19, CoronaVac, and BNT162b2 vaccines.
Letícia Carrijo Masson, Carolina do Prado Servian, Vitor Hugo Jardim, Déborah dos Anjos, Miriam Leandro Dorta, João Victor Batalha-Carvalho, Ana Maria Moro, Pedro Roosevelt Torres Romão, Menira Souza, Fabiola Souza Fiaccadori, Simone Gonçalves Fonseca   +10 more
doaj   +1 more source

Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study [PDF]

, 2022
Jing Lian Suah, Masliyana Husin, Peter Seah Keng Tok, Boon Hwa Tng, Thevesh Thevananthan, Ee Vien Low, Maheshwara Rao Appannan, Faizah Muhamad Zin, Shahanizan Mohd Zin, Hazlina Yahaya, Kalaiarasu M. Peariasamy, Sheamini Sivasampu   +11 more
openalex   +2 more sources

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers

Human Vaccines & Immunotherapeutics, 2023
The evidence on the waning protection of COVID-19 vaccines has been reviewed by the World Health Organization and has led to consideration of the need for booster doses.
Hazal Cansu Çulpan, Sümeyye Nur Aydın, Abdulkerim Uygur, Uğurcan Sayılı, Erkam Şeker, İ̇lker İnanç Balkan, Rıdvan Karaali, Beyhan Budak, Yılmaz Keskindemirci, Neşe Saltoğlu, Günay Can   +10 more
doaj   +1 more source

Side effects of CoronaVac® COVID-19 vaccination: Investigation in North Jakarta district public health center communities in Indonesia [PDF]

BackgroundThe decreasing prevalence of COVID-19 has highlighted the value of vaccinations. CoronaVac® vaccine was one of the most widely used vaccines in Indonesia, in other Southeast Asian countries, as well as in Latin America.
Alawuddin, Rizki, Araminda, Gena Nafta, Elnaem, Mohammad, Gan, Siew Hua, Khan, Kashifullah, Michael, Michael, Novarticia, Judith, Ramatillah, Diana Laila   +7 more
core   +2 more sources